This content is in French.
cfDNA put to the test in lung cancer screening
11 juin 2025
#LungCancer #EarlyDetection #LiquidBiopsy
#DNAMethylation #Diagnosis #LDCT
Lung cancer remains the leading cause of cancer-related death worldwide. This high mortality rate is largely due to the fact that diagnosis often occurs at an advanced stage, when therapeutic options are limited and less effective. In this context, early and reliable screening is essential to improve patient outcomes.
Currently, low-dose computed tomography (LDCT) is the recommended screening method for high-risk populations, particularly heavy smokers. However, its use is hindered by several limitations: a high rate of false positives leading to unnecessary invasive procedures, cumulative radiation exposure, and significant healthcare costs.
Lung cancer remains the leading cause of cancer-related death worldwide. This high mortality rate is largely due to the fact that diagnosis often occurs at an advanced stage, when therapeutic options are limited and less effective. In this context, early and reliable screening is essential to improve patient outcomes.
Currently, low-dose computed tomography (LDCT) is the recommended screening method for high-risk populations, particularly heavy smokers. However, its use is hindered by several limitations: a high rate of false positives leading to unnecessary invasive procedures, cumulative radiation exposure, and significant healthcare costs.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Machado, D. I., et al. (2025). Circulating cell-free DNA methylation as biomarker for lung cancer detection: a systematic review and meta-analysis of diagnostic studies. Systematic Reviews, 14(1), 1-17
View the source
